SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. | SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. Xu Y, Duan S, Ye W, Zheng Z, Zhang J, Gao Y, Ye S., Free PMC Article | 06/26/2024 |
New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. | New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. Jönsson ÅLM, Hilberg O, Simonsen U, Christensen JH, Bendstrup E., Free PMC Article | 06/2/2023 |
Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. | Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. Jönsson ÅLM, Hernando N, Knöpfel T, Mogensen S, Bendstrup E, Hilberg O, Christensen JH, Simonsen U, Wagner CA., Free PMC Article | 04/30/2022 |
Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. | Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. Vlasenkova R, Nurgalieva A, Akberova N, Bogdanov M, Kiyamova R., Free PMC Article | 01/22/2022 |
Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. | Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. Jönsson ÅLM, Bendstrup E, Mogensen S, Kopras EJ, McCormack FX, Campo I, Mariani F, Escribano-Montaner A, Holm AM, Martinez-Colls MDM, Pintos-Morell G, Taillé C, Crestani B, Hilberg O, Hvarregaard Christensen J, Simonsen U. | 07/10/2021 |
SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. | SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. He J, Zhou M, Li X, Gu S, Cao Y, Xing T, Chen W, Chu C, Gu F, Zhou J, Jin Y, Ma J, Ma D, Zou Q. | 12/12/2020 |
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. | Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. | 10/3/2020 |
Findings suggest that solute carrier 34 A2 (SLC34A2) might be a potential therapeutic target for the therapy of glioma patients. | Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. Bao Z, Chen L, Guo S. | 07/25/2020 |
he SLC34A2-ROS-HIF-1-induced overexpression of EZH2 promotes colorectal cancer (CRC) cells proliferation and chemo-resistance to apoptosis. SLC34A2-ROS-HIF-1-EZH2 signaling pathway might serve as a novel therapeutic target against CRC. | The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer. Li X, Xing J, Wang H, Yu E., Free PMC Article | 06/27/2020 |
The results demonstrate that miR-25/Gsk3beta-mediated activation of Wnt signaling is responsible for SLC34A2-induced enhancement of neuroblastoma cell stemness. | SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3β-mediated activation of Wnt/β-catenin signaling. Chen J, Wang P, Cai R, Peng H, Zhang C, Zhang M., Free PMC Article | 02/8/2020 |
SLC34A2 regulated sphere formation and self-renewal properties of CD44(+) gastric cancer stem cell-like cells (GCSCs), in vitro and in vivo. Mechanistic investigations revealed that Gsk3beta was the most strikingly up-regulated gene in response to SLC34A2 knockdown in GCSCs and Wnt/beta-cantenin signaling was required for SLC34A2-mediated sphere formation. | SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells. Zhang L, Guo X, Zhang L, Yang F, Qin L, Zhang D, Qin Y. | 01/5/2019 |
The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2. | Novel deletion of SLC34A2 in Chinese patients of PAM shares mutation hot spot with fusion gene SLC34A2-ROS1 in lung cancer. Dandan S, Yuqin C, Wei L, Ziheng P, Dapeng Z, Jianzhu Y, Xin X, Yonghong L, Fengjun T. | 12/22/2018 |
SLC34A2 plays a crucial promoting role in colorectal cancer development. | Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer. Liu L, Yang Y, Zhou X, Yan X, Wu Z. | 10/20/2018 |
Studied expression of solute carrier family 34 member 2 (SLC34A2/NaPi2b) in epithelial ovarian cancer using monoclonal antibody MX35 and immunohistochemistry. Different staining intensities were observed in different grades of epithelial ovarian cancer. | Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. Levan K, Mehryar M, Mateoiu C, Albertsson P, Bäck T, Sundfeldt K., Free PMC Article | 03/10/2018 |
Low SLC34A2 expression is associated with non-small cell lung cancer. | MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway. Zhang X, Ke X, Pu Q, Yuan Y, Yang W, Luo X, Jiang Q, Hu X, Gong Y, Tang K, Su X, Liu L, Zhu W, Wei Y., Free PMC Article | 01/6/2018 |
SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC. | Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity. Ye W, Chen C, Gao Y, Zheng ZS, Xu Y, Yun M, Weng HW, Xie D, Ye S, Zhang JX., Free PMC Article | 10/28/2017 |
SLC34A2 was down-regulated in osteosarcoma patients.SLC34A2 interacted with PTEN, and decreased the phosphorylation of PI3K and AKT, which inactivated the PI3K/AKT signaling pathway. | SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling. Liu X, Zhou X, Xu H, He Z, Shi X, Wu S. | 10/7/2017 |
High expression of SLC34A2 was identified in about 2/3 patients and correlated with significantly better patient's overall survival. Epidermal growth factor receptor mutations were detected in about 53% of patients with no statistically significant difference to patient's overall survival. Anaplastic lymphoma kinase rearrangement was found in 8 out of 175 patients, harboring this abnormality leads to shorter overall survi | High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients. Zhang Z, Ye S, Zhang M, Wu J, Yan H, Li X, He J. | 07/29/2017 |
a novel role of SLC34A2 inbreast cancer stem cells (BCSCs) state regulation and establishes a rationale for targeting the SLC34A2/PI3K/AKT/SOX2 signaling pathway for breast cancer therapy. | The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147(+) breast cancer stem cells. Lv Y, Wang T, Fan J, Zhang Z, Zhang J, Xu C, Li Y, Zhao G, He C, Meng H, Yang H, Wang Z, Liu J, Chen J, Wang L. | 04/22/2017 |
Knockdown of SLC34A2 inhibits proliferation. | Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. Li Y, Chen X, Lu H., Free PMC Article | 03/25/2017 |
our work indicated that decreased SLC34A2 expression sensitized BCSCs to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling and shed new light on understanding the mechanism of chemoresistance in BCSCs. This study not only bridges the missing link between stem cell-related transcription factor (Bmi1) and ABC transporter (ABCC5) but also contributes to development of potential therapeutics against breast cancer. | Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling. Ge G, Zhou C, Ren Y, Tang X, Wang K, Zhang W, Niu L, Zhou Y, Yan Y, He J. | 02/18/2017 |
Our work sheds new light on the nature of the state of lung cancer stem cell-like cells and the role of SLC34A2 in the tumorigenicity of these cells | The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells. Jiang Z, Hao Y, Ding X, Zhang Z, Liu P, Wei X, Xi J. | 02/18/2017 |
SPAK and OSR1 are powerful stimulators of the intestinal Na+-coupled phosphate co-transporter NaPi-IIb | Up-Regulation of Intestinal Phosphate Transporter NaPi-IIb (SLC34A2) by the Kinases SPAK and OSR1. Fezai M, Elvira B, Warsi J, Ben-Attia M, Hosseinzadeh Z, Lang F. | 10/1/2016 |
our data indicated that SLC34A2 could exert significantly suppressive effects on tumorigenesis and progression of NSCLC. SLC34A2 might provide new insights for further understanding the early pathogenesis of human non-small cell lung cancer | The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer. Wang Y, Yang W, Pu Q, Yang Y, Ye S, Ma Q, Ren J, Cao Z, Zhong G, Zhang X, Liu L, Zhu W., Free PMC Article | 03/19/2016 |
SLC34A2 might be associated with the initiation and progression of lung adenocarcinoma | Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells. Yang W, Wang Y, Pu Q, Ye S, Ma Q, Ren J, Zhong G, Liu L, Zhu W., Free PMC Article | 05/16/2015 |